Freeman Technology highlights relevance of the FT4 for DPI characterisation
Respiratory Drug Delivery (RDD) 2010, 25 - 29 April 2010, Florida, US
Dynamic powder characterization with the FT4 directly quantifies powder flowability and the response of a formulation to air, a critical property for successful DPI development. To ensure efficient drug delivery a DPI formulation/device combination must be engineered to achieve aerosolisation of the dose to a respirable size during use.
Research at the University of Bath has shown a robust correlation between FPD and aerated energy, a measure of how the flowability of the powder changes with the amount of air flowing through it. This makes the FT4 an extremely useful tool for the development of DPI formulations, which are required to disperse easily, with more consistent and less patient dependent performance.
The FT4 combines dynamic testing methodologies with shear and bulk property measurement, to provide comprehensive, process relevant powder characterisation. Precision engineering in combination with well-defined, automated test procedures deliver exceptional reproducibility and sensitivity. With application know-how that has been gained from 10 years working with industry, Freeman Technology also provides extensive powder processing expertise alongside the FT4 Powder Rheometer.
You may also like
Drug Delivery
Hovione and IDC open intranasal dry powder drug delivery platform for commercial partnerships
Read moreHovione and IDC have made their integrated intranasal drug delivery platform available for commercial partnerships, combining API development, particle engineering, drug product manufacturing and a single-use nasal dry powder device to accelerate development and scale-up
Trending Articles
You may also like
Drug Delivery
Hovione and IDC open intranasal dry powder drug delivery platform for commercial partnerships
Hovione and IDC have made their integrated intranasal drug delivery platform available for commercial partnerships, combining API development, particle engineering, drug product manufacturing and a single-use nasal dry powder device to accelerate development and scale-up
Manufacturing
Domino demonstrates an integrated approach to next-generation coding at Interpack 2026
At Interpack 2026, Domino Printing Sciences (Domino) will focus on the key challenges manufacturers face as variable data printing enters a new era shaped by 2D codes, intelligent automation, sustainability, and growing traceability demands. Domino specialists will be available throughout the show to highlight integrated solutions designed to work together on the factory floor – developed in collaboration with key industry partners to help to reduce complexity, risk, and operational friction for manufacturers
Manufacturing
Bristol Myers Squibb licenses Lonza ADC linker-payload technology for undisclosed target
BMS has secured exclusive access to Lonza’s SYNtecan linker-payload platform, alongside GlycoConnect and HydraSpace technologies, to advance development of an antibody-drug conjugate against an undisclosed target
Manufacturing
Former Catalent Chair and CEO George Fotiades joins eXmoor Pharma board as Chair
Angela Osborne steps back from operational duties and continues as Founder and Board Director, providing strategic continuity as eXmoor builds the leadership depth to support its expanding integrated CDMO model
Pharmaceutical
Ardena strengthens executive team to drive its next phase of growth
Ghent, Belgium, 4 May 2026 – Ardena, a specialist pharmaceutical CDMO and bioanalytical CRO enabling precision medicines and other complex therapies, announces the appointments of Ben Ash as Chief Financial Officer and Henny Zijlstra as Chief Commercial Officer. These additions further strengthen Ardena’s executive leadership team as the company continues to scale its operations and commercial reach globally